Waterview Plaza
Suite 310 2001 Route 46
Parsippany, NJ 07054
United States
855 776 6419
https://www.interpace.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 108
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Thomas W. Burnell Ph.D. | President, CEO & Chairman | 678.41k | N/A | 1963 |
Mr. Christopher McCarthy | Chief Financial Officer | 307.04k | N/A | 1992 |
Dr. Sydney D. Finkelstein | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Jody Campbell | Chief Revenue Officer | N/A | N/A | N/A |
Dr. Nicole Massoll M.D. | Chief Medical Officer | N/A | N/A | N/A |
Mr. Patrick Kane | VP & Corporate Controller | N/A | N/A | N/A |
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Interpace Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.